Advisor Group’s Akcea Therapeutics Inc AKCA Stock Holding History

Advisor Group’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-100	Closed	-$2K	–	5307
2018 Q2	$2K	Buy	+100	New	+$2.39K	﹤0.01%	4731

Other funds holding AKCA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Advisor Group's AKCA Position: Q3 2018 in Review

Advisor Group sold out of Akcea Therapeutics Inc (AKCA) in Q3 2018, closing a stake of 100 shares — an estimated $2K sold.

Advisor Group first reported a position in AKCA in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 65 funds tracked by Wall St. Rank hold AKCA as of Q3 2018.

Advisor Group reported no remaining Akcea Therapeutics Inc position as of Q3 2018 after selling out during the quarter.
Advisor Group sold 100 Akcea Therapeutics Inc shares in Q3 2018, an estimated $2K.
Advisor Group first reported a position in Akcea Therapeutics Inc in Q2 2018 and held it in 1 quarter.
Advisor Group's Akcea Therapeutics Inc position peaked at $2K in Q2 2018.
65 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q3 2018.

Based on Advisor Group's 13F filing for Q3 2018, filed 14 Nov 2018.